VB19055
/ Shenzhen Yangli Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 29, 2025
VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
(clinicaltrials.gov)
- P1 | N=86 | Recruiting | Sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
New P1 trial • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1